Piper Sandler analyst Matt O’Brien upgraded Zimmer Biomet to Overweight from Neutral as part of a broader research note on Medical Technology following the AAOS industry conference. The analyst is citing favorable commentary on the large joint market and the company’s conservative guidance.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ZBH:
- Zimmer Biomet Announces Quarterly Dividend for First Quarter of 2023
- Zimmer Biomet price target raised to $140 from $125 at Loop Capital
- Zimmer Biomet price target raised to $130 from $120 at Canaccord
- Zimmer Biomet price target raised to $137 from $135 at Truist
- Zimmer Biomet price target raised to $145 from $133 at Baird